Key Notes
- OpenEvidence and Anthropic are expanding free clinical AI support to healthcare providers in low- and middle-income countries.
- Anthropic is contributing Claude credits, dedicated engineers and funding, while OpenEvidence adapts the service to local medical guidelines and resources.
- A separate Penn Medicine partnership will develop tools with clinicians in Botswana and extend access across Penn’s US health system.
OpenEvidence and Anthropic are expanding free medical AI support to healthcare providers in roughly 100 countries, including Uganda, Angola, Sudan, Haiti and Mongolia. The collaboration targets low- and middle-income countries where clinicians can face limited access to medical journals, specialist expertise and continuing education.
The companies outlined the initiative to Reuters in a September 22 report. OpenEvidence will localize the platform, while Anthropic provides the AI technology.
Claude Credits, Engineers and Funding
Anthropic is contributing Claude credits, dedicated engineers and funding for a team working on the expansion, a company spokesperson told Fierce Healthcare. OpenEvidence founder Daniel Nadler also confirmed the partnership in the publication’s September 28 reporting.
The companies intend to make the medical research presented by the system appropriate for patients in each region. Nadler said OpenEvidence would incorporate local medical guidelines. No funding amount or detailed country-by-country deployment timetable was specified in that report.
Adapting the Tool to Local Care
OpenEvidence uses medical research and treatment guidelines to answer clinical questions. Reuters said regional adaptation would consider disease patterns, diagnostic resources, available treatments and healthcare infrastructure.
That distinction matters for practical use. A recommendation that assumes ready access to a specialist, an imaging machine or a particular medicine may offer little help where those resources are unavailable. Regional adaptation therefore concerns what a clinician can realistically do with an answer, as well as whether its supporting research is relevant.
Access and effectiveness are separate questions. Offering the software without charge removes a subscription cost, but does not establish that it improves clinical outcomes in every setting. The announcements describe an expansion and development program; they do not provide comparative patient-outcome results across the participating countries.
Penn Medicine Adds a Botswana Partnership
A separate agreement, announced by OpenEvidence and Penn Medicine on September 15, connects the company with the Botswana-UPenn Partnership. Penn teams will help develop tools around the conditions clinicians encounter in the region.
The collaboration also brings OpenEvidence to more than 10,000 clinicians across Penn Medicine’s seven-hospital US health system. The announcement describes integrating medical literature and information from electronic health records into clinical workflows, with tools accessible through Penn Medicine and the Botswana-UPenn Partnership.
Farouk Dako, who leads the Botswana-UPenn Partnership, emphasized designing the tools with local clinicians and partners. OpenEvidence’s chief medical officer, Travis Zack, said the work would include evaluating tools for different practice conditions. Those commitments outline a development process, rather than a claim that the same system is already validated for every participating health service.
Building on Existing Clinical Networks
The Botswana collaboration draws on an established network. Penn Medicine’s account of the partnership traces its work to 2001, initially supporting the country’s response to HIV. Its activities now include clinical service, research and training across a wider range of specialties.
Penn describes persistent differences in access to equipment and specialists, particularly outside major population centers. It has also worked with the University of Botswana on medical education. That history gives the AI collaboration a base of clinical relationships and local expertise on which to build.
For Anthropic, the initiative adds another healthcare application alongside its drug-discovery partnership with Novo Nordisk. The OpenEvidence project focuses on clinicians’ access to knowledge and decision support at the point of care.
OpenEvidence’s existing platform is free to clinicians in the US and Canada, according to Reuters’ corrected report.
Updated October 1, 2026, with details on Anthropic’s support and the Penn Medicine collaboration. The existing platform’s free-access geography has been corrected from the US and Europe to the US and Canada.
Disclaimer: AIstify is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, technology, software, and digital innovation sectors. These relationships do not influence AIstify’s editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.
